Financial Performance - For the first nine months of 2023, the company achieved operating revenue of RMB 197.51 billion, representing a year-on-year growth of 13.11%[5] - The net profit attributable to shareholders was RMB 3.797 billion, a decrease of 21.13% year-on-year, while the adjusted net profit was RMB 4.265 billion, reflecting an increase of 8.57%[5] - The company’s net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 3.304 billion, a decrease of 10.64% year-on-year[5] - Net profit attributable to the parent company for the first three quarters of 2023 was approximately ¥3.63 billion, down 18.4% from ¥4.45 billion in the same period of 2022[24] - Operating profit for the first three quarters of 2023 was ¥6.56 billion, down 13.93% from ¥7.62 billion in the first three quarters of 2022[22] - Net profit for the first three quarters of 2023 was ¥4.95 billion, a decrease of 17.19% compared to ¥5.98 billion in the same period of 2022[22] - Total comprehensive income for the first three quarters of 2023 was approximately ¥4.78 billion, a decrease of 15% from ¥5.61 billion in the same period of 2022[24] Revenue Breakdown - The pharmaceutical industry segment generated sales revenue of RMB 20.8 billion, with a year-on-year increase of 5.09%[5] - The traditional Chinese medicine segment reported industrial revenue of RMB 7.472 billion, marking a year-on-year growth of 16.51%[6] - The pharmaceutical distribution business achieved sales revenue of RMB 177.194 billion, a year-on-year increase of 14.17%[7] - The pharmaceutical retail business generated sales revenue of RMB 6.532 billion, reflecting a year-on-year growth of 15%[7] - The innovative drug segment saw a sales increase of 21%, with 21 new import agency contracts signed in the first three quarters of 2023[7] Research and Development - The company has three new drug applications submitted for pre-NDA or market approval, including innovative drugs WST04 and I035, both of which have received acceptance from the National Medical Products Administration in September 2023[6] - The company has achieved a total of 55 products (79 specifications) that passed the consistency evaluation for generic drugs[6] - Research and development expenses for the first three quarters of 2023 were ¥1.47 billion, an increase of 5.71% from ¥1.39 billion in the same period of 2022[21] - Research and development expenses for the first three quarters of 2023 totaled ¥280,853,232.39, down from ¥323,183,649.00 in the same period of 2022, a decrease of about 13.1%[32] Assets and Liabilities - The total assets at the end of the reporting period were RMB 213.146 billion, a 7.58% increase from the previous year[9] - Total liabilities as of September 30, 2023, were RMB 122.43 billion, compared to RMB 110.69 billion at the end of 2022, marking an increase of around 10.7%[19] - Total liabilities as of September 30, 2023, amounted to ¥133.00 billion, an increase of 10.93% from ¥120.13 billion at the end of 2022[20] - The total assets of the company reached RMB 213.15 billion, up from RMB 198.13 billion, representing a growth of about 7.6%[18] - The company's total equity decreased to ¥40,213,707,935.12 as of September 30, 2023, down from ¥40,756,350,670.90 at the end of 2022, a decline of approximately 1.3%[31] Cash Flow - Cash inflow from operating activities for the first three quarters of 2023 was approximately ¥207.17 billion, an increase of 11.5% from ¥185.77 billion in the same period of 2022[26] - Cash outflow from operating activities for the first three quarters of 2023 was approximately ¥204.87 billion, compared to ¥185.93 billion in the same period of 2022, resulting in a net cash inflow of approximately ¥2.30 billion[27] - Cash inflow from investment activities for the first three quarters of 2023 was approximately ¥25.63 billion, an increase of 12.1% from ¥22.80 billion in the same period of 2022[27] - Cash inflow from operating activities for the first three quarters of 2023 was CNY 374,593,657.45, compared to CNY 331,682,201.19 in the same period of 2022, representing an increase of approximately 12.9%[35] - Net cash flow from operating activities was negative CNY 229,646,633.04 for the first three quarters of 2023, slightly worse than the negative CNY 224,878,559.54 in 2022[35] Shareholder Information - The company reported a total of 80,053 shareholders, with 78,313 holding A-shares and 1,740 holding H-shares as of the report date[15] - The company has issued a total of 3.70 billion shares, comprising 2.78 billion A-shares and 919 million H-shares[15]
上海医药(02607) - 2023 Q3 - 季度业绩